March 22, 2023
Mar. 22, 2023 - Incyte has announced that the (FDA) has approved Zynyz (retifanlimab-dlwr), a
humanized monoclonal antibody targeting programmed death receptor-1
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Global Reach Health News
March 20, 2023
Effective 4/1/2023 As your Prescription Benefit Facilitator, BeneCard PBF is committed to providing the highest quality service, innovative clinical solutions, and valuable trend management strategies.
BeneCard PBF controls trend through several factors, including our unique pass-through model, generic maximization, clinical programs, and formulary management. The BeneCard PBF Pharmacy and Therapeutics (P&T) Committee...
BeneCard PBF controls trend through several factors, including our unique pass-through model, generic maximization, clinical programs, and formulary management. The BeneCard PBF Pharmacy and Therapeutics (P&T) Committee...
March 10, 2023
March 10, 2023 - Pfizer Inc. has announced the U.S. Food and Drug Administration (FDA) has approved Zavzpret (zavegepant), the first and only calcitonin gene-related
March 10, 2023
Mar. 10, 2023– Acadia Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration
(FDA) has approved Daybue (trofinetide) for the treatment of Rett
March 8, 2023
March 8, 2023 - March 8, 2023 - A team of researchers from Rowan-Virtua School of Osteopathic Medicine (Rowan-
Virtua SOM) and Durin Technologies, Inc., have announced
March 3, 2023
March 3, 2023 - Pharmedica USA LLC is voluntarily recalling two lots of Purely Soothing, 15% MSM Drops
to the consumer level. This product is being recalled due to non-sterility
March 1, 2023
As part of FDA’s efforts to help ensure Americans have access to compounded medicines when a
patient’s medical needs cannot be met by an FDA-approved drug
March 1, 2023
FDA has been conducting applied research on pharmacodynamic (PD) biomarkers to help facilitate
biosimilar product development